Taiwan hits cancer drug companies with fines

Taiwan’s competition authority has fined a pair of pharmaceutical companies more than €8 million for entering into an anticompetitive agreement for the exclusive distribution of colorectal cancer drugs.


Get unlimited access to all Global Competition Review content